---

---

tags : Phase 2    entities : Immunitybio inc   

save search

---

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320 |

Communications

| -2.34% | O: -0.4% H: 0.0% C: -0.58%
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -21.44% | O: -1.27% H: 0.0% C: 0.0%
phase 2 trial disease media asco cancer pancreatic

---

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -42.42% | O: 0.99% H: 8.76% C: 4.24%
treatment phase 2 cancer pancreatic pancreas enroll

---

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
Published: 2021-10-13 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 320 |

Communications

| 0.78% | O: -0.18% H: 0.0% C: 0.0%
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -43.35% | O: 0.54% H: 0.59% C: -2.15%
phase 2 cancer vaccine pancreatic pancreas enroll

---

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published: 2021-09-13 (Crawled : 13:00) - nantkwest.com
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -47.02% | O: 0.81% H: 3.11% C: -2.01%
media phase 2 phase 2/3 positive cancer trial response bladder

---

ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - nantkwest.com
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -53.95% | O: 0.97% H: 3.13% C: 2.7%
presentation phase 2 phase 2/3 results cancer trial trial results bladder

---

CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -51.75% | O: 0.28% H: 4.22% C: 3.49%
disease phase 2 phase 2/3 results trial

---

CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -54.36% | O: 0.61% H: 1.47% C: -3.12%
phase 2 results cancer trial pancreatic pancreas

---

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
Published: 2021-06-10 (Crawled : 13:15) - nantkwest.com
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -65.93% | O: 0.2% H: 2.21% C: -3.24%
phase 2 phase 1 therapy hiv phase 3 injection infections

---

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types
Published: 2021-05-20 (Crawled : 14:00) - biospace.com/
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -67.17% | O: 0.19% H: 9.44% C: 6.5%
disease phase 2 lung cancer cancer enroll

---

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
Published: 2021-05-20 (Crawled : 13:15) - nantkwest.com
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -67.17% | O: 0.19% H: 9.44% C: 6.5%
disease phase 2 lung cancer therapy cancer enroll

---

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
IBRX | $5.25 6.71% 6.29% 4.3M |

Manufacturing

| -80.43% | O: 5.86% H: 2.22% C: -13.02%
vaccine phase 1 phase 3 phase 2 cancer immunotherapy prostate cancer therapy

---

Gainers vs Losers

56%

44%

Top 10 Gainers

INVO | $1.76 131.58% 56.82% 230M |

Health Technology

SINT | $0.0365 59.39% 37.26% 470M |

Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M |

Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M |

GCTK | $0.715 36.27% 26.62% 640K |

Manufacturing

TCON | $2.33 36.26% 26.61% 2M |

Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M |

KZIA | $0.38 30.58% 23.42% 300K |

Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M |

Health Technology

ATNF | $1.91 29.05% 22.51% 310K |

---

Your saved searches

---